REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
The first pathway (see the reaction illustrated below) involves the deamination of histamine by the enzyme diamine oxidase to form imidazole acetaldehyde. In the second pathway, histamine is metabolized into Nτ-methylhistamine (also known as 1-methylhistamine), which also has some biological activity, albeit much weaker than that of histamine. Still, NMT, being a product in a reaction catalyzed by HNMT, may inhibit expression of HNMT in a negative feedback loop. This reaction is Nτ-methylation of histamine by the histamine N-methyltransferase (HNMT) enzyme. The Nτ-methylhistamine, unless excreted by the kindney, is subsequently oxidized into Nτ-methylimidazoleacetic acid (Nτ-MIAA) by the enzyme monoamine oxidase (MAO). This two-step process reduces the activity of histamine in the body and is important for quick deactivation of histamine in the brain. The third pathway is found exclusively in enterobacteria and has not been identified in mammals. This pathway involves the acetylation of histamine by an acetylase to form 4-(-acetylaminoethyl)imidazole. DAO catalyzes the oxidative deamination of polyamines, such as histamine and putrescine, to produce aminoaldehydes, hydrogen peroxide, and ammonia.
20 April – BBC News reports that the SNP will form a minority government if the Scottish Greens vote to end their power-sharing agreement. 21 April – A 20-year-old man is charged after a car appeared to drive at pro-independence marchers in Glasgow the previous day. 22 April – Donna Marie Brand, one of three people convicted of the 1996 murder of Caroline Glachan, is sentenced to life imprisonment with a minimum of 17 years. John-Paul McLaughlan is sentenced to life imprisonment with a minimum of 17 years after admitting the murder of his partner, Stacey Warnock, who was stabbed multiple times following an argument at the couple's home in December 2022. NHS Dumfries and Galloway apologises for any anxiety caused by a cyberattack, described as a "targeted and continued incursion", which occurred in March. 23 April – Two people are taken to hospital after a light aircraft crashes at Monkton near Prestwick Airport. 2024 Scottish government crisis: Patrick Harvie says he will resign as co-leader of the Scottish Greens if the party votes to end its coalition agreement with the SNP. 25 April – 2024 Scottish government crisis: The Scottish National Party's coalition in the Scottish government with the Scottish Greens collapses as the SNP withdraws. The SNP announce their intention to continue as a minority government. The Scottish Conservatives call a no confidence vote in First Minister Humza Yousaf. 26 April – 2024 Scottish government crisis: Humza Yousaf says he will not resign as first minister of Scotland despite facing a motion of no confidence in his government.
Patients with active internal bleeding Patients with a recent (within 3 months) hemorrhagic stroke Patients with a recent (within 2 months) intracranial/intraspinal surgery/severe head trauma Trauma patients with an increased risk of life-threatening bleeding Patients with an epidural catheter Patients with a known or suspected intracranial neoplasm or mass lesion Patients with known hypersensitivity to drotrecogin or any component
In September 2014, the company acquired Innopharma for $225 million, plus up to $135 million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs. On January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human cytomegalovirus. In February 2015, the company received approval from the Food and Drug Administration for palbociclib (Ibrance) for treatment of certain types of breast cancer. In March 2015, the company announced it would restart its collaboration with Eli Lilly and Company surrounding the Phase III trial of Tanezumab. In May 2015, Pfizer and a Bar-Ilan University laboratory announced a partnership based on the development of medical DNA nanotechnology. In June 2015, the company acquired Nimenrix and Mencevax, meningococcal vaccines, from GlaxoSmithKline for around $130 million. In September 2015, Pfizer acquired Hospira for $17 billion, including the assumption of debt. Hospira was the largest producer of generic injectable pharmaceuticals in the world. On November 23, 2015, Pfizer and Allergan announced a planned $160 billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's Republic of Ireland domicile, resulting in the new company being subject to corporation tax at the relatively low rate of 12.5%.
=== Musculoskeletal effects === Skeletal muscle tremor is the most common adverse effect of beta-agonists, and is more likely to be seen after oral administration than after inhalation. Tremor results from an imbalance between fast- and slow-twitch muscle groups of the extremities, and its severity varies greatly between individuals.
Sources: en.wikipedia.org
Famous examples of modern anthropomorphic taxidermy include the work of artist Adele Morse, who gained international attention with her "Stoned Fox" sculpture series, and the work of artist Sarina Brewer, known for her Siamese twin squirrels and flying monkeys partaking in human activities.
==== Off-farm/market efficiency ==== Besides streamlining farm production, digital agriculture technologies can make agricultural markets more efficient. Mobile phones, online ICTs, e-commerce platforms, digital payment systems, and other digital agriculture technologies can mitigate market failures and reduce transaction costs throughout the value chain.
Notch proteins are a family of type 1 transmembrane proteins that form a core component of the Notch signaling pathway, which is highly conserved in animals. The Notch extracellular domain mediates interactions with DSL family ligands, allowing it to participate in juxtacrine signaling. The Notch intracellular domain acts as a transcriptional activator when in complex with CSL family transcription factors. Members of this type 1 transmembrane protein family share several core structures, including an extracellular domain consisting of multiple epidermal growth factor (EGF)-like repeats and an intracellular domain transcriptional activation domain (TAD). Notch family members operate in a variety of different tissues and play a role in a variety of developmental processes by controlling cell fate decisions. Much of what is known about Notch function comes from studies done in Caenorhabditis elegans (C. elegans) and Drosophila melanogaster. Human homologs have also been identified, but details of Notch function and interactions with its ligands are not well known in this context.
The common procedure involves undertaking a 24-hour urine collection, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken. The urinary flow rate is still calculated per minute, hence:
=== Republic of Egypt (from 1953) === King Hussein of Jordan, 1955 Marshal Josip Broz Tito, President of the Federal People's Republic of Yugoslavia, 1956 Prof. Amintore Fanfani, Prime Minister and ad-interim Minister of Foreign Affairs of the Republic of Italy, 1959 Yuri Gagarin, Soviet cosmonaut, 1961 Taha Hussein, Egyptian writer, 1965 Umm kulthum, Egyptian singer and actress, 1965 Mohammed Abdel Wahab, Egyptian singer and composer, 1965 President Jimmy Carter, President of the United States, 1979 Emperor Akihito of Japan Emperor Amha Selassie of Ethiopia Mohammed Burhanuddin, 52nd Da'i al-Mutlaq of the Dawoodi Bohra, 1978 King Bhumibol Adulyadej of Thailand Mohamed ElBaradei, former director general of the International Atomic Energy Agency (IAEA) Queen Elizabeth II, 1975 Birendra Bir Bikram shah Dev, King of Nepal, 1974 Mohammad Reza Pahlavi, Shah of Iran, 1975 Hassaballah El Kafrawy, Egyptian former Minister of Housing Pengiran Anak Haji Mohamed Yusof, prince consort and cheteria of Brunei, 1984 Naguib Mahfouz, Egyptian writer, 1988 King Fahd bin Abdulaziz Al Saud of Saudi Arabia, 1989 Pierre Gemayel, founder of the Lebanese Phalange Emperor Haile Selassie of Ethiopia King Hamad bin Isa Al Khalifa of Bahrain, 2016 King Idris of Libya (Grand Cordon) Ekmeleddin İhsanoğlu, Turkish academic, diplomat and former Secretary-General of the Organisation of Islamic Cooperation (OIC) Émile Lahoud, President of Lebanon, 2000 Makarios III, former president of Cyprus Nelson Mandela, President of South Africa Adly Mansour, former Chief Justice of the Supreme Constitutional Court and former acting President of Egypt King Mohammed VI of Morocco Muhammad Naguib, First President of Egypt Nursultan Nazarbayev, President of Kazakhstan Antonín Novotný, President of Czechoslovakia Sultan Qaboos bin Said al Said of Oman, 1976 Ziaur Rahman, President of Bangladesh Heinrich Rau, East German politician (Grand Cordon), 1961 King Saud bin Abdulaziz Al Saud of Saudi Arabia, 1954 King Norodom Sihanouk of Cambodia William E. Simon, U.S. Secretary of the Treasury Suharto, President of Indonesia Field Marshal Mohamed Hussein Tantawi, former chairman of the Supreme Council of the Armed Forces of Egypt, 2012 Walter Ulbricht, President of East Germany, 1965 George Vasiliou, former president of Cyprus Sir Magdi Habib Yacoub, Egyptian professor of Cardiothoracic Surgery Professor Ahmed Zewail, Egyptian scientist Katerina Sakellaropoulou, President of Greece, 2020 Salva Kiir Mayardit, President of South Sudan, 2020 Haitham bin Tariq, Sultan of Oman, 2023 Narendra Modi, Prime Minister of India, 2023 Mufaddal Saifuddin, 53rd Da'i al-Mutlaq of the Dawoodi Bohras, 2023 Mishal Al-Ahmad Al-Jaber Al-Sabah, Emir of Kuwait, 2024 King Frederik X, King of Denmark, 2024 King Felipe VI, King of Spain, 2025 Donald Trump, President of the United States, 2025
Sources: en.wikipedia.org
A dough conditioner (also called a flour treatment agent, improving agent or bread improver) is any substance added to bread dough to strengthen its texture or otherwise improve it in some way. Dough conditioners may include enzymes, yeast nutrients, mineral salts, oxidants and reductants, bleaching agents and emulsifiers. Flour treatment agents are used to increase the speed of dough rising and to improve the strength and workability of the dough.
==== Narcolepsy ==== Narcolepsy is a chronic sleep-wake disorder that is associated with excessive daytime sleepiness, cataplexy, and sleep paralysis. Patients with narcolepsy are diagnosed as either type 1 or type 2, with only the former presenting cataplexy symptoms. Type 1 narcolepsy results from the loss of approximately 70,000 orexin-releasing neurons in the lateral hypothalamus, leading to significantly reduced cerebrospinal orexin levels; this reduction is a diagnostic biomarker for type 1 narcolepsy. Lateral hypothalamic orexin neurons innervate every component of the ascending reticular activating system (ARAS), which includes noradrenergic, dopaminergic, histaminergic, and serotonergic nuclei that promote wakefulness. Amphetamine's therapeutic mode of action in narcolepsy primarily involves increasing monoamine neurotransmitter activity in the ARAS. This includes noradrenergic neurons in the locus coeruleus, dopaminergic neurons in the ventral tegmental area, histaminergic neurons in the tuberomammillary nucleus, and serotonergic neurons in the dorsal raphe nucleus. Dextroamphetamine, the more dopaminergic enantiomer of amphetamine, is particularly effective at promoting wakefulness because dopamine release has the greatest influence on cortical activation and cognitive arousal, relative to other monoamines. In contrast, levoamphetamine may have a greater effect on cataplexy, a symptom more sensitive to the effects of norepinephrine and serotonin.
=== Monitoring of human exposure === Pentachlorophenol may be measured in plasma or urine as an index of excessive exposure. This is usually performed by gas chromatography with electron-capture or mass-spectrometric detection. Since urine contains predominantly conjugated PCP in chronic exposure situations, prior hydrolysis of specimens is recommended. The current ACGIH biological exposure limits for occupational exposure to PCP are 5 mg/L in an end-of-shift plasma specimen and 2 mg/g creatinine in an end-of-shift urine specimen.
Other requirements considered when designing operando experiments include reagent and product flow rates, catalyst position, beam paths, and window positions and sizes. All of these factors must also be accounted for while designing operando experiments, as the spectroscopic techniques used may alter the reaction conditions. An example of this was reported by Tinnemans et al., which noted that local heating by a Raman laser can give spot temperatures exceeding 100 °C. Also, Meunier reports that when using DRIFTS, there is a noticeable temperature difference (on the order of hundreds of degrees) between the crucible core and the exposed surface of the catalyst due to losses caused by the IR-transparent windows necessary for analysis.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.